PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Aldesleukin

Drugs in development · updated 30 October 2026

Aldesleukin: clinical trials and development status

Other names and codes: Proleukin

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Aldesleukin is in 30 active clinical trials (recruiting or ongoing, phases I–III) for 52 diseases. The most advanced phase is II.

30Active trials
IIMost advanced phase
52Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Aldesleukin and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 52 diseases.

DiseaseMost advanced phaseActive trialsReference trial
MelanomaII8NCT05155033
Ovarian neoplasmII8NCT03412877
Non-small-cell lung carcinomaII6NCT03412877
Breast neoplasmII5NCT03412877
MetastasisII4NCT05686226
Renal cell carcinomaII4NCT05155033
Stomach neoplasmI–II4NCT05267626
Lung neoplasmII3NCT02133196
Multiple myelomaII3NCT03412877
Pancreatic neoplasmII3NCT01174121
Triple-negative breast neoplasmII3NCT03449108
Urogenital neoplasmII3NCT03412877
Uterine cervix neoplasmII3NCT05686226
Anus neoplasmII2NCT05686226
Colorectal neoplasmII2NCT01174121
Gastrointestinal neoplasmI–II2NCT03190941
Oropharyngeal NeoplasmsII2NCT05686226
Penile neoplasmII2NCT05686226
SarcomaII2NCT03449108
Vaginal neoplasmII2NCT05686226
Vulvar neoplasmII2NCT05686226
AdenocarcinomaII1NCT02133196
Adenosquamous carcinomaII1NCT02133196
Alzheimer's diseaseII1NCT05468073
Anaplastic thyroid carcinomaII1NCT03449108
Bladder neoplasmI–II1NCT05267626
Bone neoplasmII1NCT03449108
Colonic neoplasmI–II1NCT03190941
Endometrial neoplasmII1NCT01174121
Gastrointestinal stromal tumorII1NCT07647068

Everything on Aldesleukin

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch